Abcellera Biologics Inc ABCL

$12.08 +0.26 (2.20%)

Valuation

Market cap
3,624,142,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
3,038,300
Avg volume
5,160,680
Day's range
$11.78 – $12.41
Shares out
306,611,000
Stochastic %K
56%
Beta
1.41
Analysts
Strong Sell
Price target
$16.82

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

Stocktradesmoon Oct 27, 11:58 AM
$ABCL 👀 $ABCL put in a nice deep retracement into the weekly OB. I have alerts set for the daily MSB level at $12.37.
0 replies
Stocktradesmoon Oct 27, 9:00 AM
$ABCL Almost every $ABCL conversation here is about 635. The quieter thread is the T-cell engager platform. A US patent on CD3 T-cell engagers, US 12,735,494 B2, lists AbCellera as assignee.
0 replies
Stocktradesmoon Oct 27, 8:31 AM
$ABCL First, the potential of solid tumor TCEs. Following recent data from Amgen, clinical evidence is now accumulating from Xencor as well. This represents an industrially significant trend for AbCellera, which is developing solid tumor TCEs with Jazz. Second, the importance of CD3 antibody design technology. This can be linked to AbCellera's recently examined CD3 antibody composition-of-matter patents. However, Xencor uses its own technology, so this doesn't mean the antibodies from the two companies are identical. Third, the reality of competition. Xencor has demonstrated initial anti-tumor activity in actual patients. In contrast, AbCellera's collaboration with Jazz is still in the stage of awaiting concrete clinical outcomes.
0 replies
Stocktradesmoon Oct 27, 8:29 AM
$ABCL The fact that TCE technology is demonstrating real therapeutic potential even in solid tumors is positive. However, at the same time, the competitive bar that AbCellera must clear going forward is also rising. Xencor presented Phase 1 clinical data for the ENPP3 × CD3 T-cell engager antibody XmAb819 at ESMO 2026. Among 11 patients with evaluable advanced renal cancer at the selected dose, 5 responded, achieving an objective response rate of 45.5% and an estimated 6-month progression-free survival rate of **82%**. That said, this is still a small early-stage clinical trial, and further validation is needed for severe adverse reactions and the durability of therapeutic effects. The connections I see as particularly important are three-fold.
0 replies
SuperGreenToday Oct 27, 7:19 AM
$ABCL Share Price: $12.06 Contract Selected: Apr 16, 2027 $10 Calls Buy Zone: $3.60 – $4.44 Target Zone: $6.03 – $7.36 Potential Upside: 58% ROI Time to Expiration: 170 Days | Updates via https://fxcapta.com/stockinfo/
0 replies
Stocktradesmoon Oct 27, 5:12 AM
$ABCL Watching a break above PWH which also lines up with todays high
0 replies
Stocktradesmoon Oct 27, 4:17 AM
$ABCL Part 2) To me, the collective hiring pattern is much more interesting than any individual opening. It suggests AbCellera is investing heavily in the capabilities required for later-stage development. Does this confirm Phase 3? No. But these are exactly the kinds of capabilities I’d expect a company to build as it prepares for that possibility. The market is focused on the next data readout. I’m also watching how AbCellera is positioning itself for what comes AFTER the data. The pieces are coming together. 🧬🚀
0 replies
Stocktradesmoon Oct 27, 4:16 AM
$ABCL PART 1) 🚨 $ABCL — ANOTHER INTERESTING HIRING DEVELOPMENT! 🧬 AbCellera’s careers board now shows a NEW Senior Clinical Scientist position, adding to what I believe is a very telling pattern of clinical-development hiring. Look at some of the positions we’ve identified recently: 🔬 Senior Clinical Scientist — NEW 📊 Senior Director, Clinical Data Management 📈 VP, Biometrics 🩺 VP, Medical Affairs 📋 Associate Director, Regulatory Affairs 🏭 VP, Late-Stage & Commercial Biologics Development This is not the hiring profile of a company focused exclusively on antibody discovery anymore. We’re talking about building the infrastructure needed to design, execute, analyze, regulate, and eventually commercialize increasingly complex clinical programs. And remember, ABCL635’s 12-week Phase 2 data is still ahead of us.
1 replies